Athira Pharma, Inc.
https://athira.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Athira Pharma, Inc.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Defender’s Scopolamine Nasal Gel Secures Pivotal Win In Motion Sickness
The US firm’s nasal gel formulation of the anticholinergic compound has succeeded in a second Phase III trial, bringing Defender closer to entering a market dominated by Bayer’s Transderm Scop.
Athira's Alzheimer's Drug Passes Futility Analysis; Data Targeted For 2024
An unblinded interim efficacy analysis by a DMC recommended a Phase II/III study testing fosgonimeton in Alzheimer's patients should continue.
Rising Tide Lifts Many Ships In Wake Of Eisai/Biogen’s Lecanemab Readout
Eisai and Biogen had double-digit stock price gains based on the positive Phase III readout for lecanemab. The good news also lifted competitors Lilly and Roche as well as earlier-stage Alzheimer’s drug developers.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Other Names / Subsidiaries
-
- M3 M3 Biotechnology, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice